Testing for discordance at metastatic relapse of breast cancer matters

Journal of Clinical Oncology

Volumn 30, Issue 24, 2012, Pages 3031-

  Van Diest, Paul J ^a   Hoefnagel, Laurien D C ^a   Van Der Wall, Elsken ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR;

ANTIGENICITY; BREAST BIOPSY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CLINICAL DECISION MAKING; CLINICAL FEATURE; HUMAN; LETTER; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL;

BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 84865261459     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.6734     Document Type: Letter

References (5)

1. Chia S: Testing for discordance at metastatic relapse: Does it matter? J Clin Oncol 30:575-576, 2012
2. Amir E, Miller N, Geddie W, et al: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30:587-592, 2012
3. Niikura N, Liu J, Hayashi N, et al: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30:593-599, 2012
4. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al: Receptor conversion in distant breast cancer metastases. Breast Cancer Res 12:R75, 2010
5. Hoefnagel LD, Moelans CB, Meijer SL, et al: Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer [epub ahead of print on March 13, 2012]